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Background:MYC is amplified in approximately 15% of breast cancers (BCs) and is associated with poor outcome. c-MYC protein
is multi-faceted and participates in many aspects of cellular function and is linked with therapeutic response in BCs. We
hypothesised that the functional role of c-MYC differs between molecular subtypes of BCs.
Methods: We therefore investigated the correlation between c-MYC protein expression and other proteins involved in different
cellular functions together with clinicopathological parameters, patients’ outcome and treatments in a large early-stage
molecularly characterised series of primary invasive BCs (n¼ 1106) using immunuohistochemistry. The METABRIC BC cohort
(n¼ 1980) was evaluated for MYC mRNA expression and a systems biology approach utilised to identify genes associated with
MYC in the different BC molecular subtypes.
Results: HighMYC and c-MYC expression was significantly associated with poor prognostic factors, including grade and basal-like
BCs. In luminal A tumours, c-MYC was associated with ATM (P¼ 0.005), Cyclin B1 (P¼ 0.002), PIK3CA (P¼ 0.009) and Ki67
(Po0.001). In contrast, in basal-like tumours, c-MYC showed positive association with Cyclin E (P¼ 0.003) and p16 (P¼ 0.042)
expression only. c-MYC was an independent predictor of a shorter distant metastases-free survival in luminal A LNþ tumours
treated with endocrine therapy (ET; P¼ 0.013). In luminal tumours treated with ET,MYCmRNA expression was associated with BC-
specific survival (P¼ 0.001). In ER-positive tumours, MYC was associated with expression of translational genes while in ER-
negative tumours it was associated with upregulation of glucose metabolism genes.
Conclusions: c-MYC function is associated with specific molecular subtypes of BCs and its overexpression confers resistance to
ET. The diverse mechanisms of c-MYC function in the different molecular classes of BCs warrants further investigation particularly
as potential therapeutic targets.
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In a meta-analysis of 3797 patients, V-Myc Avian Myelocytoma-
tosis Viral Oncogene Homolog (MYC) is amplified in 15.7% of
breast cancers (BCs) and is associated with higher tumour grade,
advanced stage and progesterone receptor (PgR)-negative tumours
resulting in an association with poor overall survival and disease
recurrence independent of existing prognostic factors (Deming
et al, 2000). The c-MYC protein is multi-faceted and participates in
many aspects of cellular function, including replication, growth,
metabolism, differentiation and apoptosis (Liao and Dickson,
2000). The mechanisms of c-MYC action in controlling these
different roles remain poorly understood. However, it may be
context or isoform dependent whether c-MYC promotes cell
proliferation or apoptosis (Deming et al, 2000; Liao and Dickson,
2000; Patel et al, 2004).
The expression of c-MYC is regulated by oestrogen via the
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI-3 kinase) path-
ways, among other signalling pathways, promoting cell proliferation
and survival (Liao et al, 2000). Antioestrogen treatment, including
aromatase inhibitors, tamoxifen and faslodex, all downregulate MYC
mRNA inducing cell cycle arrest (Carroll et al, 2002). There is also
strong evidence that c-MYC has a role in the development of
antioestrogen resistance where it is frequently overexpressed during
progression and distant relapse of oestrogen receptor (ER)-positive
BCs treated with adjuvant hormonal therapy (Planas-Silva et al,
2007). Clinical evidence also suggests that c-MYC and B-cell CLL/
lymphoma 2 (Bcl-2) act in concert to promote lymph node
metastasis in early BCs (Sierra et al, 1999). c-MYC overexpression
can also cause DNA damage and subsequently trigger apoptosis via
DNA damage response pathways. ATM serine/threonine kinase
(ATM), a critical DNA double-strand break repair protein, is
upregulated in response to such DNA damage and is necessary for
p53 activation and suppression of tumour development.
In a recent study, it was demonstrated that c-MYC expression was
upregulated through the cross-talk between ER and human
epidermal growth factor receptor 2 (HER2) in BC cells (Chen et al,
2015). Cross-talk between ER and HER2 regulates c-MYC-mediated
glutamine metabolism in aromatase inhibitor-resistant BC cells.
Therapeutic strategies aimed at targeting c-MYC have emerged,
including interfering with c-MYC synthesis, dimerisation, stability
and transcriptional activity (Vita and Henriksson, 2006; Albihn
et al, 2010; Boddupally et al, 2012; Dang, 2012). However, the
effectiveness of targeting c-MYC using single agents and failure to
achieve long-lasting efficacy is observed because MYC function
controls the expression of multiple genes and cancer cells can
recover from oncogene addiction.
Thus targets aimed at inhibiting downstream signalling path-
ways in c-MYC-dependent tumours such as stress-response,
metabolism and cell cycle pathways are currently the focus for
new therapeutic opportunities (Dang, 2012). Several clinical trials
focussed on these biological processes are currently underway
(Horiuchi et al, 2014).
In this study, we hypothesised that the functional role of c-MYC
differs between molecular subtypes of BCs and would influence the
response for different type of adjuvant therapeutic regimens. We
therefore investigated the correlation betweenMYCmRNA and c-MYC
protein expression and other proteins involved in cell proliferation,
DNA damage and apoptosis, in addition to clinicopathological
parameters, outcome and treatments in a large cohort of molecularly
characterised early-stage invasive primary breast carcinoma.
MATERIALS AND METHODS
MYC gene expression. MYC gene expression was evaluated in a
cohort of 1980 BC samples using the Molecular Taxonomy of
Breast Cancer International Consortium (METABRIC) cohort
(Curtis et al, 2012). RNA from fresh frozen tumours were subject
to transcriptional profiling using the Illumina HT-12 v3 platform
(San Diego, CA, USA), and the data were preprocessed and
normalised as described previously (Curtis et al, 2012). In this
cohort, patients with ER-positive and/or lymph node-negative
tumours did not receive adjuvant chemotherapy, whereas those
with ER-negative and/or lymph node-positive tumours received
adjuvant chemotherapy.
c-MYC protein expression
Study patients. Immunohistochemistry was conducted using a
large cohort of patients comprising a well-characterised consecu-
tive series of early stage (TNM Stages I–III excluding T3 and T4
tumours) sporadic primary operable invasive BCs from patients
(age p70 years) enrolled into the Nottingham Tenovus Primary
Breast Carcinoma Series who presented at the Nottingham City
Hospital between 1989 and 1998 (n¼ 1106) and managed in
accordance to a uniform protocol. Patients’ clinical history,
tumour characteristics, information on therapy and outcomes are
prospectively maintained. Outcome data were collected on a
prospective basis and included development and time to distant
metastasis (DM) and BC-specific survival (BCSS). DM-free
survival is defined as the time (in months) from the date of
primary surgery to the appearance of DM. The BCSS is defined as
the time (in months) from the date of primary surgery to the date
of BC-related death. Luminal tumours were defined as ERþ ;
triple-negative status were all those tumours not expressing ER,
PgR and HER2; and HER2þ status was defined as all tumours
overexpressing HER2 irrespective of ER status. Patients
with luminal tumours had the best BCSS followed by those with
triple-negative tumours (Supplementary Figure S1). Patients with
HER2þ tumours had the poorest outcome.
Validating antibody specificity. The specificity of the anti-c-MYC
primary antibody (Clone 9E100; Abcam Ltd, Cambridge, UK) was
validated using western blotting (WB). WB was performed on
whole-cell lysates of MDA-MB-468 human BC cell line (obtained
from the American Type Culture Collection; Rockville, MD, USA)
using 1 : 500 dilution of the primary antibody dilution, and
1 : 15000 horseradish peroxidase-conjugated secondary antibody
(SA) (Li-cor Biosciences, Cambridge, UK). 5% milk (Marvel
Original Dried Skimmed Milk, Premier Food Groups Ltd, St
Albans, UK) was used for blocking. HRP-conjugated Anti-Rabbit
b-actin (Clone AC-15; Sigma, Gillingham, UK) at 1 : 5000 was used
as a house-keeping protein. A protein ladder (PageRuler Plus
Prestained Protein Ladder, ThermoScientific, Waltham, MA, USA)
was included. Chemiluminescence was used to visualise bands
using Odyssey Fc (Li-cor Biosciences, Lincoln, NE, USA), which
showed a single specific band at the right size (41 KDa) for c-MYC
protein, confirming the specificity of the antibody (Supplementary
Figure S2A).
Tissue arrays and immunohistochemistry. Tumour samples were
arrayed as previously described (Abd El-Rehim et al, 2005). In
brief, tissue cores with a diameter of 0.6mm were punched from
the representative tumour regions of each donor block. Cores were
precisely arrayed into a new recipient paraffin blocks using a tissue
microarrayer (Beecher Instruments, Sun Prairie, WI, USA).
Immunohistochemical staining was performed on 4-mm thick
sections using Novolink polymer detection system (Leica Biosys-
tems, Newcastle, UK, RE7150-K), composed of Peroxidase Block,
Post Primary Block, Novolink Polymer, 3,30-diaminobenzidine
(DAB) chromogen and substrate buffer and Novolink haematox-
ylin. Briefly, tissue slides were deparaffinised with xylene and
rehydrated through three changes of alcohol. Heat-induced antigen
epitope retrieval was performed in citrate buffer (pH 6.0) for
20min using a microwave oven. Endogenous peroxidase activity
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was blocked by Peroxidase Block for 5min. Slides were washed
with Tris-buffered saline (TBS, pH 7.6), followed by application of
Protein Block for 5min. Following another TBS wash, mouse
monoclonal primary antibody for c-MYC (Clone 9E100; Abcam
Ltd) at 1 : 100 in Leica antibody diluent (RE7133) was applied and
incubated for 45min. Slides were washed with TBS followed by
incubation with Post Primary Block for 30min followed by a TBS
wash. Novolink polymer was applied for 30min. DAB working
solution made up of 1 : 20 DAB chromogen in DAB substrate
buffer was prepared and applied for 5min. Slides were counter-
stained with Novolink haematoxylin for 6min, dehydrated and
coverslipped. Negative (omission of the primary antibody) and
positive controls were included according to the manufacturer’s
datasheet of each antibody. Immunhistochemical staining and
dichotomisation of the other biomarkers included in this study
were as per previous publications (Rakha et al, 2007; Elsheikh et al,
2008; Rakha et al, 2009; Aleskandarany et al, 2010a,b, 2011, 2012;
Habashy et al, 2013; Barros et al, 2014; Supplementary Table S1).
Evaluation of immunohistochemical staining. Assessment of
staining was estimated subjectively on intensity corresponding to
negative, weak, moderate and strong nuclear and/or cytoplasmic
staining. Dichotomisation of c-MYC protein expression was
based on the mean resulting in negative/weak (MYC negative)
and moderate/strong (MYC positive) groups, which were selected
prior to analysis.
Artificial neural network (ANN) model. A nonlinear ANN
modelling-based approach was utilised to identify those gene
probes associated with high MYC expression in ER-positive
and -negative disease using the METABRIC cohort. A total of
48 803 probes were screened for each sample. The data-mining
algorithm comprised a three layer multilayer perception architec-
ture modified with a feed forward back-propagation algorithm and
a sigmoidal transfer function, as previously described (Lancashire
et al, 2010; Abdel-Fatah et al, 2014). The network momentum and
learning rate were, respectively, set as 0.1 and 0.5. A parsimonious
structure using two hidden nodes and three split Monte Carlo
Cross validation were utilised to prevent over fitting. The output
node was coded as 0 if a case was low MYC expression (median)
and as 1 if it was above the median expression value. Inputs were
ranked in ascending order based on their average classification
error for the test subset. The top 200 predictive genes identified
were then applied to an ANN-based network inference algorithm
as described in earlier studies. This model predicted a weighted
link (direction and magnitude) between each of the top 200 gene
probe markers associated with MYC expression and every other
marker in the top 200. The 100 strongest interactions based on
the magnitude were then visualised as a map with Cyto-scape
(Smoot et al, 2011).
External validation cohorts. For external validation of MYC
mRNA expression, bc-GenExMiner v3.0 (Breast Cancer Gene-
Expression Miner v3.2) online data set (http://bcgenex.centregau-
ducheau.fr) was used. In this study, the gene correlation-targeted
analysis offering the possibility to evaluate the correlation between
MYC and candidate genes in ERþ and ER BCs was used
(Jezequel et al, 2012).
Statistical analysis. Statistical analysis was performed using the
SPSS 21.0 statistical software (SPSS Inc., Chicago, IL, USA).
Univariate and multivariate analyses were performed by chi-
squared test, Log rank and Cox regression analysis, respectively.
Survival curves were analysed by the method of Kaplan–Meier. A
P-value o0.01 was considered significant. This study complied
with reporting recommendations for tumour marker prognostic
studies criteria (McShane et al, 2005). Recursive partitioning
(Hothorn et al, 2006) was used to identify a cutoff in gene
expression values such that the resulting subgroups have
significantly different survival courses.
Ethics. This study was approved by the Nottingham Research
Ethics Committee 2 under the title ‘Development of a molecular
genetic classification of breast cancer’.
RESULTS
MYC expression and clinicopathological parameters. HighMYC
mRNA expression was observed in 260 out of 1977 (13.1%)
tumours. Positive cytoplasmic and nuclear expression of c-MYC
protein was observed in 559 out of 1106 (50.5%) of invasive BC
cases while 547 (49.5%) were negative Supplementary Figures S2B
and C.
There was significant association between MYC mRNA and
c-MYC protein expression with poor prognostic indicators of BCs.
High MYC mRNA expression was associated with high grade
(Po0.001) and Nottingham Prognostic Index (P¼ 0.001) but not
size or lymph node stage (Table 1). Positive c-MYC protein
expression was significantly associated with higher tumour grade
(P¼ 0.043), mitotic frequency scores (P¼ 0.004), nuclear pleom-
porphism (P¼ 0.012) and lymph node stage (P¼ 0.046, Table 1).
c-MYC was also significantly associated with histological tumour
type where more expression was observed in medullary-like
tumours (22 out of 31, 71.0%) but was less likely to be expressed
in lobular tumours (41 out of 106, 38.7%). However, there was no
association between c-MYC and patient age, tumour size, tubule
formation or lymphovascular invasion.
MYC expression and biomarkers. High MYC mRNA expression
was significantly associated with ER and PgR-negative tumours
(both Po0.001), HER2-positive (P¼ 0.001) as well as triple-
negative tumours (Po0.001, Table 1). There was no association
between c-MYC protein expression with ER, PgR nor HER2
(Table 1). Positive c-MYC protein expression was associated with
markers of basal-like phenotype, including cytokeratin 5/6 and
epidermal growth factor receptor (EGFR; P¼ 0.002 and 0.001,
respectively, Table 2).
c-MYC expression was significantly expressed in breast tumours
with high ATM and PI-3 kinase (both P¼ 0.001, Table 2). Cell
cycle regulators p16, Cyclin B1 and Cyclin E were also significantly
expressed in breast tumours with positive expression of c-MYC
(P¼ 0.018, P¼ 0.023 and P¼ 0.001, respectively). Tumours with
high c-MYC showed high expression of Ki67 (Po0.001). There
was no association between c-MYC expression and BCL2, p53,
p21, pAKTs473 or Retinoblastoma (Rb).
MYC expression in molecular BC subtypes. In terms of the
intrinsic subtypes (PAM50), high MYC mRNA expression
was significantly expressed in basal tumours (Po0.001), whereas
low expression was associated with luminal A and HER2 tumours
(both Po0.001). There was no association between MYC
expression and luminal B tumours.
Those biomarkers that were associated with high c-MYC
expression in the unselected breast tumours were further
investigated in the different BC molecular classes. This showed
differential association between molecular classes. In luminal A
(ERþ /HER2 ) tumours, c-MYC expression was significantly
associated with ATM (P¼ 0.005), Cyclin B1 (P¼ 0.002), PIK3CA
(P¼ 0.009) and Ki67 (Po0.001) but not Cyclin E nor p16
(Table 2). In contrast, in basal-like tumours, c-MYC expression
was associated with positive Cyclin E (P¼ 0.003) and p16
(P¼ 0.042) expression but not with ATM, Cyclin B1, PI-3 kinase
or Ki67 (Table 2). In HER2þ tumours, positive c-MYC expression
was associated with ATM (P¼ 0.001) and Ki67 (P¼ 0.030)
expression only.
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Table 1. c-MYC expression in relation to clinicopathological parameters
mRNA Protein
Low, n (%) High, n (%) X2 (P-value) Negative, n (%) Positive, n (%) X2 (P-value)
Size, cm
o1 82 (89.1) 10 (10.9) 4.05 (0.256) 34 (50.7) 33 (49.3) 0.109 (0.991)
1–2 683 (89.2) 83 (10.8) 299 (49.6) 304 (50.4)
42–5 868 (86.7) 133 (13.3) 208 (49.3) 214 (50.7)
45 82 (83.7) 16 (16.3) 6 (46.2) 7 (53.8)
Total 1715 (87.6) 242 (12.4) 547 (49.5) 558 (50.5)
Grade
1 157 (92.9) 12 (7.1) 25.85 (o0.001) 110 (57.3) 83 (43.0)
2 700 (90.9) 70 (9.1) 177 (50.0) 177 (50.0) 6.72 (0.043)
3 794 (83.6) 156 (16.4) 258 (46.6) 296 (53.4)
Total 1651 (87.4) 238 (12.6) 545 (49.5) 556 (50.5)
Tubules
1 Not available 30 (63.8) 17 (36.2)
2 172 (47.3) 192 (52.7) 4.59 (0.101)
3 318 (49.5) 325 (50.5)
Total 520 (49.3) 534 (50.7)
Pleomorphism
1 Not available 13 (54.2) 11 (45.8)
2 225 (55.0) 184 (45.0) 8.88 (0.012)
3 282 (45.6) 336 (54.4)
Total 520 (40.5) 531 (50.5)
Mitosis
1 Not available 203 (56.4) 157 (43.6)
2 81 (44.3) 102 (55.7) 11.08 (0.004)
3 236 (46.2) 275 (53.8)
Total 520 (49.3) 534 (50.7)
Tumour type
Ductal (including mixed) Not available 437 (47.4) 484 (52.6)
Lobular 65 (61.3) 41 (38.7) 25.48 (o0.001)
Medullary-like 9 (29.0) 22 (71.0)
Other special types 31 (73.8) 11 (26.20
Total 542 (49.3) 558 (50.7)
Axillary nodal stage
1 918 (88.7) 117 (11.3) 354 (52.4) 321 (47.6)
2 275 (87.6) 39 (12.4) 2.30 (0.316) 148 (44.4) 185 (55.6) 6.14 (0.046)
3 536 (86.2) 86 (13.8) 43 (46.2) 50 (53.8)
Total 1729 (87.7) 242 (12.3) 545 (49.5) 556 (50.5)
Nottingham Prognostic Index
p3.4 361 (92.3) 30 (7.7) 178 (52.5) 161 (47.5)
43.4 1280 (86.4) 202 (13.6) 10.12 (0.001) 365 (47.9) 397 (52.1) 1.99 (0.158)
Total 1641 (87.6) 232 (12.4) 543 (49.3) 558 (50.7)
ER
Negative 362 (77.0) 108 (23.0) 63.65 (o0.001) 134 (48.4) 143 (51.6) 0.25 (0.615)
Positive 1370 (90.9) 137 (9.1) 411 (50.1) 409 (49.9)
Total 1732 (87.6) 245 (12.4) 545 (49.6) 552 (50.3)
PgR
Negative 791 (84.5) 145 (15.5) 15.724 (o0.001) 219 (49.2) 226 (50.8) 0.003 (0.959)
Positive 941 (90.4) 100 (9.6) 311 (49.1) 323 (50.9)
Total 1732 (87.6) 245 (12.4) 530 (49.1) 549 (50.9)
HER2
Negative 1501 (86.7) 131 (13.3) 11.49 (0.001) 477 (48.4) 477 (51.6) 0.79 (0.375)
Positive 231 (94.3) 145 (5.7) 85 (52.1) 78 (47.9)
Total 1732 (82.2) 376 (17.8) 562 (50.3) 555 (49.7)
Triple negative
No 1508 (90.8) 152 (9.2) 99.85 (o0.001) 453 (50.6) 443 (49.4) 2.93 (0.087)
Yes 224 (70.7) 93 (29.3) 84 (43.8) 108 (56.3)
Total 1732 (87.6) 245 (12.4) 537 (49.4) 551 (50.6)
Pam50 gene signature
Luminal A 675 (94.4) 40 (5.6) 38.19 (o0.001) Not available
Luminal B 439 (89.8) 50 (10.2) 0.69 (0.408)
HER2 232 (97.5) 6 (2.5) 20.92 (o0.001)
Basal 227 (68.8) 103 (31.2) 162.42 (o0.001)
Total 1573 (88.8) 199 (11.2)
Abbreviations: ER¼oestrogen receptor; HER2¼human epidermal growth factor receptor 2; PgR¼progesterone receptor. Bold numerals signify P-values.
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MYC expression and patients’ outcome. The high expression of
MYC mRNA (P¼ 0.007, Figure 1A) and c-MYC protein
(P¼ 0.001, Figure 1B) were both significantly associated with
poor patient BCSS. There remained significant differences with
respect to positive c-MYC expression in the survival of patients in
both Stage I (P¼ 0.016) and Stage II (P¼ 0.010) (Figures 1C
and D) but not Stage III (P¼ 0.458) disease (data not shown).
Moreover, there was a significant association between positive
c-MYC protein expression and shorter DM-free survival in
unselected breast tumours (P¼ 0.017, Figure 1E), which was
maintained in luminal A tumours (P¼ 0.013, Figure 1F) but not in
basal-like or HER2þ tumours (Figures 1G and H). c-MYC
expression was associated with the development of bone metastases
(P¼ 0.019) in unselected tumours, while in the luminal A
population positive c-MYC expression was associated with liver
metastases (P¼ 0.039).
In terms of adjuvant treatment, positive c-MYC expression
significantly predicted a shorter DM-free survival in luminal A
tumours treated with endocrine therapy (P¼ 0.002, Figure 1I) but
not in patients who did not receive adjuvant therapy (Figure 1J).
Additionally, the prediction of a shorter DM-free survival in
luminal A tumours treated with adjuvant endocrine therapy was
observed in LNþ tumours (Figure 1K, P¼ 0.012) but not in LN
tumours (Figure 1L). In multivariate Cox regression analysis,
c-MYC remained an independent predictor of a shorter DM-free
survival in luminal A LNþ tumours treated with endocrine
therapy (P¼ 0.013, Table 3).
Regulation of genes by MYC in biological subtypes. Top pair-
wise interactions for genes probe markers associated with MYC
expression in ER-positive and -negative tumours showed several
different hubs indicated to be highly influential or regulated in the
MYC system.
In ER-positive disease, MYC mRNA was significantly associated
with genes implicated in translational (initiation elongation and
termination) together with cellular protein metabolism (Table 4).
In addition, the high expression of MYC was associated with the
downregulation of several key hubs, including genes for translocase
of outer mitochondrial membrane 40 homolog (yeast)-like
(TOMM40L) and pre-B-cell leukaemia homeobox interacting
protein 1 (PBXIP1; Figure 2A).
In contrast, within ER-negative disease, MYC mRNA was
significantly associated with genes associated with glucose
homeostasis, glucose metabolism and glucose transport (Table 4).
MYC was also associated with upregulation by several genes of
which calcium channel flower domain containing 1 (CACFD1) and
proline dehydrogenase (oxidase) 1 (PRODH) were centralised hubs
(Figure 2B).
DISCUSSION
Studies that address the prognostic significance of c-MYC protein
and its influence on the response of therapeutic regimens are
limited. In the current study, a large number of breast tumours
were investigated for MYC mRNA and c-MYC protein expression
in order to better understand the potential roles of this complex
protein in BCs.
There is a wealth of studies that describe MYC amplifications in
BCs, although the frequency of this amplification is highly variable
(Borg et al, 1992; Rummukainen et al, 2001; Robanus-Maandag
et al, 2003; Schlotter et al, 2003; Adem et al, 2004; Al-Kuraya et al,
2004; Rodriguez-Pinilla et al, 2007; Cancer Genome Atlas Network,
2012). In this study, the expression of MYC that was observed in
13.2% of breast tumours is, however, in line with the large meta-
Table 2. c-MYC expression in relation to molecular breast cancer subtypes and biomarkers
All cases Luminal A Basal-like HER2þ
c-MYC c-MYC c-MYC
Negative Positive
X2
(P-value) Negative Positive
X2
(P-value) Negative Positive
X2
(P-value) Negative Positive
X2
(P-value)
ATM
Negative 204 (55.9) 161 (44.1) 11.68 (0.001) 120 (58.0) 87 (42.0) 7.71 (0.005) 43 (46.7) 49 (53.3) 0.15 (0.697) 37 (60.7) 24 (39.3) 11.45 (0.001)
Positive 143 (42.9) 190 (57.1) 108 (44.8) 133 (55.2) 19 (43.2) 25 (56.8) 12 (27.3) 32 (72.7)
Total 347 (49.7) 351 (50.2) 228 (50.9) 220 (49.1) 62 (45.6) 74 (54.4) 49 (46.7) 56 (53.3)
PIK3CA
Negative/
low
134 (59.8) 90 (40.2) 13.67 (0.001) 132 (46.8) 150 (53.2) 9.47 (0.009) 13 (50.0) 13 (50.0) 0.67 (0.717) 12 (63.2) 7 (36.8) 2.93 (0.302)
Medium 117 (44.7) 145 (55.3) 92 (45.5) 110 (54.5) 12 (40.0) 18 (60.0) 10 (40.0) 15 (60.0)
High 239 (46.6) 274 (53.4) 103 (59.9) 69 (40.1) 51 (42.1) 70 (57.9) 53 (52.5) 48 (47.5)
Total 490 (49.0) 509 (51.0) 327 (49.8) 329 (50.1) 76 (42.9) 101 (57.1) 75 (51.7) 70 (48.3)
Cyclin B1
Negative 200 (51.2) 191 (48.8) 5.21 (0.023) 136 (54.6) 113 (45.4) 9.55 (0.002) 28 (36.4) 49 (63.6) 0.57 (0.449) 32 (56.1) 25 (43.9) 0.56 (0.455)
Positive 138 (42.6) 186 (57.3) 83 (40.1) 124 (59.9) 24 (42.9) 32 (57.1) 27 (49.1) 28 (50.9)
Total 338 (47.3) 377 (52.7) 219 (48.0) 237 (52.0) 52 (39.0) 81 (41.0) 59 (34.5) 112 (65.5)
Cyclin E
Negative 215 (52.4) 195 (47.6) 10.55 (0.001) 147 (49.3) 151 (50.7) 1.50 (0.220) 26 (61.9) 16 (38.1) 8.67 (0.003) 36 (50.0) 24 (40.0) 1.95 (0.163)
Positive 36 (34.6) 68 (65.4) 13 (38.2) 21 (61.8) 16 (31.4) 35 (68.6) 6 (40.0) 9 (60.0)
Total 251 (48.8) 263 (51.2) 160 (48.2) 172 (51.8) 42 (45.2) 51 (54.8) 42 (56.0) 33 (44.0)
P16
Negative 356 (51.5) 335 (48.5) 5.62 (0.018) 264 (51.1) 253 (48.9) 3.37 (0.066) 37 (55.2) 30 (44.8) 4.15 (0.042) 47 (49.5) 48 (50.5) 0.47 (0.494)
Positive 142 (43.6) 184 (56.4) 62 (42.5) 84 (50.8) 46 (39.7) 70 (60.3) 32 (55.2) 26 (44.8)
Total 498 (49.0) 519 (51.0) 326 (49.2) 337 (50.8) 83 (45.4) 100 (54.6) 79 (51.6) 74 (48.4)
Ki67
Negative 176 (59.7) 119 (40.3) 20.71 (o0.001) 149 (58.9) 104 (41.1) 13.45 (o0.001) 10 (55.6) 8 (44.4) 1.59 (0.207) 15 (71.4) 6 (28.6) 4.73 (0.030)
Positive 266 (43.5) 345 (56.5) 148 (43.7) 191 (56.3) 58 (40.0) 87 (60.0) 52 (49.6) 62 (54.4)
Total 442 (48.8) 464 (51.2) 297 (50.2) 295 (49.8) 68 (41.7) 95 (58.3) 63 (48.1) 68 (51.9)
Abbreviation: HER2¼human epidermal growth factor receptor 2. Bold numerals signify P-values.
MYC in breast cancer subtypes BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.46 921
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2Pr
ob
ab
ilit
y 
of
 s
ur
vi
va
l
Pr
ob
ab
ilit
y 
of
 s
ur
vi
va
l
1.0
0.8
0.6
0.4
0.2
0.0
Pr
ob
ab
ilit
y 
of
 s
ur
vi
va
l
0.0
A B C
F
LKJ
ED
G H I
1.0
0.8
0.6
0.4
0.2Pr
ob
ab
ilit
y 
of
 s
ur
vi
va
l
0.0
1.0
0.8
0.6
0.4
0.2
Pr
ob
ab
ilit
y 
of
 d
ist
an
t m
et
as
ta
se
s
Pr
ob
ab
ilit
y 
of
 d
ist
an
t m
et
as
ta
se
s
0.0
1.0
0.8
0.6
0.4
0.2
Pr
ob
ab
ilit
y 
of
 d
ist
an
t m
et
as
ta
se
s
0.0
1.0
0.8
0.6
0.4
0.2
0.0
Pr
ob
ab
ilit
y 
of
 d
ist
an
t m
et
as
ta
se
s
Pr
ob
ab
ilit
y 
of
 d
ist
an
t m
et
as
ta
se
s
Pr
ob
ab
ilit
y 
of
 d
ist
an
t m
et
as
ta
se
s 1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
Pr
ob
ab
ilit
y 
of
 d
ist
an
t m
et
as
ta
se
s
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
Pr
ob
ab
ilit
y 
of
 d
ist
an
t m
et
as
ta
se
s
1.0
0.8
0.6
0.4
0.2
0.0
0 100 200 300 400 0 100 200 300 4000
P =0.007
P =0.010
P =0.856 P =0.558
n =85
n =78
n =129
n =140
P =0.001
P =0.017 P =0.013
P =0.002
P =0.353P =0.012P =0.589
P =0.016
n =245
n =205
n =201
n =87
n =109
n =174
n =96
n =42
n =59n =180 n =70
n =547
n =559 n =362
n =359
n =1732
n =449
n =467
n =207
n =189
100 200 300 400
Breast cancer-specific survival (months)
0 20 40 60 80 100 120 0 20 40 60 80 100 120
Distant mestastases-free survival (months) Distant metastases-free survival (months)
0 20 40 60 80 100 1200 20 40 60 80 100 1200 20 40 60 80 100 120
Distant metastases-free survival (months)Distant metastases-free survival (months)Distant metastases-free survival (months)
0 20 40 60 80 100 120
Distant metastases-free survival (months)
0 20 40 60 80 100 120
Distant metastases-free survival (months)
0 20 40 60 80 100 120
Distant metastases-free survival (months)
Breast cancer-specific survival (months)Breast cancer-specific survival (months)
0 100 200 300 400
Breast cancer-specific survival (months)
Figure 1. MYC and BC patient outcome: (A) MYC (BCSS), (B) c-MYC (BCSS), (C) c-MYC in Stage I disease (BCSS), (D) c-MYC in Stage II disease
(BCSS), (E) c-MYC (DMFS), (F) c-MYC in luminal A tumours (DMFS), (G) c-MYC in basal-like tumours (DMFS), (H) c-MYC in HER2þ tumours (DMFS),
(I) c-MYC in luminal A tumours treated with endocrine therapy (DMFS), (J) c-MYC in luminal A tumours with no adjuvant treatment (DMFS), (K)
c-MYC in luminal A lymph node-positive patients treated with endocrine treatment, (L) c-MYC in luminal A lymph node-negative patients treated
with endocrine treatment. Abbreviations: DMFS¼distant metastases-free survival; Green¼positive; blue¼negative. A full color version of this
figure is available at the British Journal of Cancer journal online.
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analysis study showing amplification of MYC in 15.7% of BCs
(Deming et al, 2000). Additionally, MYC expression was similarly
associated with higher tumour grade and poor patient survival as
observed with MYC amplification (Deming et al, 2000).
The expression of c-MYC protein was observed in 52.2% of
invasive BCs, which is within the range of other immunohisto-
chemical studies (45–94%) (Spandidos et al, 1989; Spaventi et al,
1994; Naidu et al, 2002). Although in this study the correlation
between measurements of mRNA expression and those for protein
expression was not perfect, MYC gene amplification has been
reported to be significantly associated with overexpression of its
mRNA and protein. Moreover, some authorities have reported
MYC gene amplification in 15% of breast tumours, whereas mRNA
level was overexpressed in 22–35% of tumours. However, up to
40% of breast tumours showed MYC protein overexpression. These
figures indicate that MYC overexpression could be attributed to
different mechanisms, including gene amplification, transcriptional
regulation and mRNA and protein stabilisation (reviewed in Xu
et al, 2010). Therefore, variation between gene and protein
expression is likely. When tumours were stratified according to
histological type, medullary-like tumours showed the highest
frequency of c-MYC expression, whereas most of the lobular
carcinoma showed low c-MYC expression. This is consistent with
Table 3. Multivariate analysis of c-MYC in luminal A lymph
node-positive breast tumours treated with adjuvant
endocrine therapy
Parameter Hazard ratio 95% CI P-value
c-MYC 1.86 1.06–3.26 0.031
Sizea 0.98 0.57–1.69 0.943
Gradea 3.64 1.96–6.76 0.015
Stage 3.64 1.96–6.76 0.001
Age (X50 years) 0.75 0.34–1.67 0.481
Abbreviation: CI¼ confidence interval.
aFitted as a linear term, that is, increase in risk for change one unit in grade or size.
Table 4. Top pair-wise analysis of genes associated with highMYC expression in ER-positive and -negative breast tumours in the
METABRIC data set and pair-wise correlation cross-validation in Breast Cancer Gene-Expression Miner
Genes Gene ontology—biological process
Correlation with MYC using Breast Cancer
Gene-Expression Miner
ER-negative tumours
AKT1 Glucose homeostasis; glucose metabolic process; glucose transport Po0.0001 (n¼ 1560)
FABP5 Glucose transport Po0.0001 (n¼ 1353)
FGFR4 Glucose homeostasis Po0.0001 (n¼ 1502)
FOXA1 Glucose homeostasis Po0.0001 (n¼ 1526)
IRS2 Glucose metabolic process Po0.0001 (n¼ 1501)
PTPN2 Glucose homeostasis Po0.0001 (n¼ 1502)
SEH1L Glucose transport Po0.0001 (n¼ 1326)
TFAP2B Glucose homeostasis; glucose metabolic process Po0.0001 (n¼ 1355)
CACFD1 Calcium ion transmembrane transport Po0.0001 (n¼ 1282)
PRODH Proline catabolic process Po0.0001 (n¼ 582)
ER-positive tumours
EIF4A1 Translational initiation; cellular protein metabolic process Po0.0001 (n¼ 3834)
EIF4H Translational initiation P¼ 0.04 (n¼ 3769)
RPL13A Translational initiation; translational elongation; cellular protein metabolic process;
translational termination
Po0.0001 (n¼ 3427)
RPL17 Translational initiation; translational elongation; cellular protein metabolic process;
translational termination
Po0.0001 (n¼ 3654)
RPL18A Translational initiation; translational elongation; cellular protein metabolic process;
translational termination
Po0.0001 (n¼ 3449)
RPL8 Translational initiation; translational elongation; cellular protein metabolic process Po0.0001 (n¼ 3710)
RPL9 Translational initiation; translational elongation; cellular protein metabolic process;
translational termination
Po0.0001 (n¼ 3453)
RPLP0 Translational initiation; translational elongation; cellular protein metabolic process;
translational termination
Po0.0001 (n¼ 3518)
RPS5 Translational initiation; translational elongation; cellular protein metabolic process;
translational termination
Po0.0001 (n¼ 3653)
EEF1B2 Translational elongation; cellular protein metabolic process Po0.0001 (n¼ 3810)
ATF3 Cellular protein metabolic process Po0.0001 (n¼ 3714)
CCT7 Cellular protein metabolic process Po0.0001 (n¼ 4056)
HSPD1 Cellular protein metabolic process Po0.0001 (n¼ 3454)
TUBB6 Cellular protein metabolic process Po0.0001 (n¼ 3835)
TOMM40L Ion, protein and transmembrane transport Po0.0001 (n¼ 2418)
PBXIP1 Cell differentiation; negative regulation of transcription Po0.0001 (n¼ 3875)
Abbreviations: ER¼oestrogen receptor; METABRIC¼Molecular Taxonomy of Breast Cancer International Consortium.
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version of this figure is available at the British Journal of Cancer journal online.
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previous studies that observed rare MYC amplification/c-MYC
protein overexpression in lobular carcinomas, whereas it is more
frequent in non-lobular breast carcinomas (Spaventi et al, 1994;
Janocko et al, 2001).
In this study, high expression of MYC was associated with higher
tumour grade and the basal-like phenotype. This is in agreement
with previous clinicopathological studies (Deming et al, 2000; Liao
and Dickson, 2000; Rummukainen et al, 2001; Naidu et al, 2002;
Schmitt and Reis-Filho, 2002; Shanmugham et al, 2004; Rodriguez-
Pinilla et al, 2007; Cancer Genome Atlas Network, 2012). However,
there was a lack of significant relation with tumour size or hormone
receptor status; absence of these relationships have been demon-
strated in previous studies (Spandidos et al, 1989; Naidu et al, 2002).
These findings are not surprising in view of the multifunctional
nature of MYC oncogene, with pivotal roles in proliferation,
differentiation and cell death.
In the whole cohort, high MYC and c-MYC expression was
associated with poor patient survival. Additionally c-MYC
predicted a shorter metastatic-free survival, and this significance
was maintained in multivariate analysis independently of tumour
grade, nodal stage and size. Moreover, the relation between c-MYC
and the development of resistance to antioestrogen treatment has
been addressed in many studies (Santos et al, 1988; Venditti et al,
2002; McNeil et al, 2006; Planas-Silva et al, 2007; Musgrove et al,
2008) and is in agreement with our observations in relation
between high c-MYC expression and shorter DM-free survival in
those patients who received hormonal treatment and was an
independent prognostic indicator for such group. Unlike Roux-
Dosseto et al (1992), there was no significant association between
tumour relapse and c-MYC expression in lymph node-negative
patients. c-MYC protein may affect the response to chemotherapy
probably through DNA damage response regulation (Berns et al,
1992a,b; Nass and Dickson, 1997; Gewirtz et al, 1998;
Aulmann et al, 2006) although in the current study we found no
evidence for this. Interestingly, MYC amplification in colon
carcinoma predicts better response to 5-FU adjuvant chemother-
apy (disease-free and cancer-specific survivals have been improved
by 30%) (Arango et al, 2001; Barratt et al, 2002) but only in p53
wild-type tumours. Although this type of study in BCs has not
been published yet, Rakha et al (2007) described improvement of
the poor prognosis of basal subtype of triple-negative BCs by
treatment with chemotherapy. These tumours often have amplified
EGFR gene (Reis-Filho et al, 2005) and according to the described
MYC co-amplification in BCs (Al-Kuraya et al, 2004; Miura et al,
2008), and the association between c-MYC expression and basal-
like BCs, we may hypothesise the possibility that c-MYC
overexpression may contribute to favourable response to che-
motherapy, specially whose which contain 5-FU. Suppression of
C-MYC transcription in BC cells after 5-FU treatment supports the
direct effect of 5-FU on the oncogene activity, probably mediated
by upstream signalling inhibition (Hernandez-Vargas et al, 2006).
We observed that c-MYC expression in luminal A tumours was
associated with negative/low PI-3 kinase expression. Indeed, using
a mouse BC model, PIK3CA-driven recurrent tumours with MYC
amplification can lead to the inactivation of PIK3CA and remain
independent of the PI-3 kinase pathway resulting in tumours
developing resistance to PI-3 kinase pathway-specific targeted
therapies (Liu et al, 2011). This could suggest that luminal A
tumours, compared with other biological subtypes of BCs, are
more susceptible to PI-3 kinase inhibitor resistance. Within
luminal A tumours, high c-MYC expression was also associated
with an increase in cell cycle activity indicated by high expression
of Cyclin B1 and Ki67. Regulation of cyclin B1 is essential for the
initiation of mitosis as it regulates the G2–M transition of the cell
cycle. MYC regulates the CCNB1 gene promoter and the high
expression of Cyclin B1 seen in the luminal A tumours, which has
previously been associated with poor prognosis of hormone
receptor-positive BCs (Hu et al, 2006; Agarwal et al, 2009), is
most likely as a consequence of this regulation.
In basal-like tumours, c-MYC expression was associated with
Cyclin E and the cyclin-dependent kinase inhibitor p16. p16 has
previously been associated with ER-negative BCs and poor patient
outcome particularly those treated with adjuvant chemotherapy
(Dublin et al, 1998; Han et al, 2001; Nemtsova et al, 2007). Both
cyclin-E and p16 are inextricably linked with the G1–S-phase
transition of the cell cycle. c-MYC is an upstream activator of
cyclin-E/CDK2 activity and promotes cell cycle progression from
G1 to S phase independent of the Rb pathway and can compensate
for low cyclin D/cdk4 kinase activity (Gray-Bablin et al, 1996;
Alevizopoulos et al, 1997), whereas p16 arrests this transcriptional
activity at the G1 phase. Rb is thought to promote an aggressive
form of triple-negative BCs with MYC overexpression, although in
the current study we found no evidence that RB was associated
with c-MYC expression in any BC biological subtype (Knudsen
et al, 2015). The p16 protein has a very long half-life (Sherr, 1996)
and therefore accumulates in the cells with increasing number of
cell cycles. This might partly explain high p16 expression in
tumours with high growth fraction.
Although co-amplification of MYC and HER2 has previously
been associated with very poor patient outcome in BCs by
promoting a stem-like phenotype (Nair et al, 2014), we found no
evidence to suggest this particularly as there was a negative
relationship between MYC expression and HER2 status. We did,
however, observe that in HER2þ tumours there was a significant
relationship between c-MYC protein and high cell proliferation, as
determined by Ki67, suggesting that co-expression is linked with
more aggressive tumours. Conversely, there was also high
correlation with the co-expression of c-MYC and ATM in
HER2þ , suggesting that, while these tumours are highly
proliferative, they are also undergoing higher levels of cell cycle
arrest, DNA repair or apoptosis by MYC activating ATM-
dependent checkpoint responses (Guerra et al, 2010).
The mechanisms of MYC were further explored in ER-positive
and -negative tumours using ANN analysis of the METABRIC
data. Here we show that MYC is potentially driving glucose
metabolism in ER-negative, but not in ER-positive, tumours
providing necessary energy required for cell proliferation (the
Warburg effect), a key feature of these poor prognostic tumours. It
is well-documented that c-MYC regulates glucose metabolism and
glutamine uptake and contributes to the metabolic preprogram-
ming required for cancer cells to adapt to the tumour
microenvironment (for reviews, see Li and Simon, 2013;
Wahlstrom and Arsenian Henriksson, 2015). Our data confirm
previous studies in triple-negative breast tumours where those with
MYC gene copy gain have increased glucose uptake (Palaskas et al,
2011) and the expression of thioredoxin-interacting protein is
downregulated driving the activation of glucose metabolism (Shen
et al, 2015). A mechanistic association between MYC and glucose
metabolism in endocrine resistance in BCs has also recently been
described (Shajahan-Haq et al, 2014).
In ER-positive tumours, MYC was associated with translational
function, particularly the family of ribosomal subunit proteins and
eukaryotic translation-initiation factors. Increases in rRNA synthesis,
ribosomal biogenesis and translational initiation/elongation are
common cancer features, which can be driven by MYC (for a review,
see Ruggero, 2009), and we show that enhanced ribosome assembly
and transcriptional activity is a probable feature of luminal BCs.
CONCLUSIONS
Although MYC is multifunctional, it is apparent that different
biological pathways are predominant in the separate molecular
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subtypes of BCs. The diverse mechanisms of c-MYC function as
potential therapeutic targets, particularly in BC subtypes, therefore
warrants further investigation.
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